Skip to content

Cancers & treatments

News & evidence

Living with cancer

Learn & contribute

Loading

A public, cited, editable map of oncology: technologies, targets, products, companies, institutions, pathways, trials, pairings, roadmaps, and ideas. One page per object, with a plain-language TL;DR on every page.

Work in progress. Every fact on this site is being built and checked in the open and may be incomplete, out of date, or wrong. You must do your own research and verify anything here at its primary source before relying on it. Nothing on this site is medical advice; decisions belong with you and your clinicians.

OnCo is an information resource, not medical advice. Nothing here replaces a conversation with a qualified clinician. Never delay care because of something you read here; in an emergency, call your local emergency services. Terms of use

Browse by cancer
Tags
Search
Connections
For me
Navigator
Biomarker matrix
Calculators
Interactions
Decision aids
Checkpoint side effects
Tumour board
Compare
Counts by category
Rankings
Timeline
Year by year
Query builder
Graph explorer
Saved
Body map

Cancers & treatments

News & evidence

Institutions & people

Institutions
Universities
Trial leadership
People
Heroes and heroines
Companies
Startups
Requests for startups
Investors
Company scorecards
Trial sponsors
Manufacturing map
Countries
United States deep dive
India deep dive
China deep dive
Germany deep dive
Israel deep dive
United Kingdom deep dive
Cases by country
Funding flows

Living with cancer

For me
The first 60 days
Appointment prep pack
Side effects
Symptom to test
Report reader
Survivorship planner
Second opinion
Financial help
Free in oncology
Paying for care in the US
NHS coverage
Paying for care in India
Coverage rankings
Cutting cancer care costs
Diet, exercise and lifestyle
Supportive care
Recovery and rejuvenation
Complementary and supportive approaches
Hair loss and regrowth
What comes back after treatment
Heroes and heroines

Learn & contribute

Reading paths
About & methodology
Roadmap
Gaps to fill
Coverage of the field
Review queue
Reviewer roster
Contributors
Idea votes
Teaching packs
Weekly issue
Suggest an edit
Answer quality
Data dictionary
Build on OnCo
Open API
Open data
Open tools
Open source in oncology
The software of oncology
GitHub

© 2026 OnCo. Code MIT. The data are free for individual and educational use with the attribution “Data from OnCo (onco.cc)”, under CC BY-NC 4.0. Commercial use must contact us to pay for the data. Commercial licences. Made with heart and soul by Jude Gomila .

About and methodology Corrections Open API Tags Terms of use Privacy policy GitHub

Loading

Home
Trials
Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance

trialsTrialActive

Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance

A phase 3 trial of Ropeginterferon alfa-2b and Anagrelide in myeloproliferative neoplasms, run by PharmaEssentia, active and no longer recruiting.

Also called: SURPASS ET

Overview Connected6

Overview

Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance is a phase 3 interventional study registered as NCT04285086 by PharmaEssentia, with 174 participants enrolled, started 2020-08-25 and due to reach its primary completion in 2024-11-12. Interventions recorded: Ropeginterferon alfa-2b and Anagrelide.

Setting

A Phase 3, Open-Label, Multicenter, Randomized, Active-controlled Study to Assess PK and Compare the Efficacy, Safety, and Tolerability of P1101 vs Anagrelide as 2nd Line Therapy for Essential Thrombocythemia (SURPASS ET): The Core Study and Its Extension Study.

Phase

Phase 3

Sponsor

PharmaEssentia

Registry

Started

2020-08-25

Enrolled

174 enrolled

Connected

Similar pages

Trial
A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET
Shares PharmaEssentia, Ropeginterferon alfa-2b, Essential thrombocythaemia (ET), Cytokines & engineered cytokines and the tag pipeline.
Trial
Extension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET Patients
Shares PharmaEssentia, Ropeginterferon alfa-2b, Essential thrombocythaemia (ET), Cytokines & engineered cytokines and the tag pipeline.
Trial
A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV
Shares PharmaEssentia, Ropeginterferon alfa-2b, Cytokines & engineered cytokines, Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
Trial
A Study to Access Efficacy and Safety of P1101 in Chinese PV Patients Who Are Intolerant or Resistance to HU
Shares PharmaEssentia, Ropeginterferon alfa-2b, Cytokines & engineered cytokines, Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
Treatment
Bomedemstat
Shares Essential thrombocythaemia (ET), Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
Trial
Study to Assess SLN124 in Patients With Polycythemia Vera
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
Trial
A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms
Shares Essential thrombocythaemia (ET) and the tag pipeline.
Trial
A Study of LY2784544 in Participants With Myeloproliferative Neoplasms
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.

cancers

Essential thrombocythaemia (ET)Myeloproliferative neoplasms (PV, ET, myelofibrosis)

technologies

Cytokines & engineered cytokines

drugs

ApprovedOral platelet-lowering agent (imidazoquinazoline)

Anagrelide · Agrylin / Xagrid

ApprovedLong-acting mono-pegylated interferon alfa

Ropeginterferon alfa-2b · Besremi

companies

Evidence strength46/100 · Emerging

How much and what kind of evidence, not how big the benefit. Click for the breakdown.

Phase 3+30
174 enrolled+11
No structured primary endpoint0
Result: active0
No independent replication recorded0
A linked product is approved+5

Formula disclosed on the evidence page.

ProvenanceLast edited 2026-09-22 · Jude Gomila · Wave 2 corpus-only joins applied · diff · file

Sources & links

ClinicalTrials.gov NCT04285086

Data

JSON ·

Follow this page

Wrong or missing?

Propose a change with a source. Organisations can update their own records. Every suggestion is reviewed, safety-checked and validated before it goes live; nothing is edited directly.

Suggest an editDiscuss start a thread

Out of date?
Report a readout
How review works

Cancers

Myeloproliferative neoplasms (PV, ET, myelofibrosis)
Essential thrombocythaemia (ET)

Technologies

Cytokines & engineered cytokines

Products

Ropeginterferon alfa-2b
Anagrelide

Companies

PharmaEssentia

Not yet reviewedNeeds expert (clinical) review. Review this page or see the review queue and roster.

Model panel commentary is coming to this page: machine commentary, not clinical review.

Machine-readable versions of Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance

JSON record with neighbours
Markdown context for language models
RDF Turtle for this record (its triples, relations and owl:sameAs; the IRI of this record is https://onco.cc/trials/nct04285086/)
All trials as JSON
RDF N-Triples for the whole corpus
Search index: id, kind, name, TL;DR and route for every record
OpenAPI 3.1 description
API root and meta.json
llms.txt

MCP server: npx -y onco-mcp, tools search, get_entity, list_kind, ask, context, compare. This record is get_entity or context with id nct04285086.

WebMCP tools registered on this page: onco_search, onco_get_entity.